NLSP

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

NLS Pharmaceutics AG

NASDAQ | NLSP

1.77

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$7.48M

Market Cap

-

P/E Ratio

-1.74

EPS

$5.64

52 Week High

$1.30

52 Week Low

HEALTHCARE

Sector

NLSP Chart

Recent Chart
Price Action

NLSP Technicals

Tags:

NLSP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$3.3K
Total Revenue $0
Cost Of Revenue $3.3K
Costof Goods And Services Sold $3.3K
Operating Income -$4.4M
Selling General And Administrative $3.2M
Research And Development $422K
Operating Expenses $4.4M
Investment Income Net -
Net Interest Income -$150K
Interest Income -
Interest Expense $150K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.3K
Income Before Tax -$2M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$2M
Comprehensive Income Net Of Tax -
Ebit -$3.6M
Ebitda -$3.6M
Net Income -$2M

Revenue & Profitability

Earnings Performance

NLSP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $2.2M
Total Current Assets $2.2M
Cash And Cash Equivalents At Carrying Value $1.7M
Cash And Short Term Investments $1.7M
Inventory -
Current Net Receivables $400K
Total Non Current Assets $7.6K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $160K
Other Non Current Assets -
Total Liabilities $827K
Total Current Liabilities $827K
Current Accounts Payable $515K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $185K
Other Non Current Liabilities -
Total Shareholder Equity $1.4M
Treasury Stock -
Retained Earnings -$74M
Common Stock $166K
Common Stock Shares Outstanding $1.5M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$4.3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $3.3K
Capital Expenditures $3.9K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$3.9K
Cashflow From Financing $5M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$2M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$3.3K
Total Revenue $0
Cost Of Revenue $3.3K
Costof Goods And Services Sold $3.3K
Operating Income -$4.4M
Selling General And Administrative $3.2M
Research And Development $422K
Operating Expenses $4.4M
Investment Income Net -
Net Interest Income -$150K
Interest Income -
Interest Expense $150K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.3K
Income Before Tax -$2M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$2M
Comprehensive Income Net Of Tax -
Ebit -$3.6M
Ebitda -$3.6M
Net Income -$2M

NLSP News

NLSP Profile

NLS Pharmaceutics AG Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

NLS Pharmaceutics AG is a biopharmaceutical firm based in Stans, Switzerland, focused on the innovative discovery and development of drug therapies targeting rare and complex central nervous system disorders. The company aims to address significant unmet medical needs through its pipeline of novel therapeutics, leveraging its proprietary technologies and research efforts. NLS Pharmaceutics is positioned to be a key player in the CNS market, with a commitment to improving patient outcomes through advancements in pharmacotherapy.

VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
PFE
-0.30%
$24.70
RR
+7.85%
$6.38
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
IREN
+8.04%
$64.58
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
MULN
-55.00%
$0.63
BINI
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
HOOD
+1.03%
$140.40
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
PFE
-0.30%
$24.70
RR
+7.85%
$6.38
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
IREN
+8.04%
$64.58
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
MULN
-55.00%
$0.63
BINI
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
HOOD
+1.03%
$140.40
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.